Symbio, based in NY, is a global full-service Clinical Research Organization (CRO) with offices in the US and Europe. In November 2023, Symbio merged with CA-based Dow Development Laboratories and Germany’s Proinnovera to form one of the largest dermatology-focused CROs. In September 2024, the group was renamed to Symbio.

Symbio specializes in Proof-of-Concept, medical device, and Phase I to IV clinical studies, and has completed over 650 studies both in the US and Europe. The newly formed organization will leverage the combined power of highly experienced teams with deep expertise in the dermatology space to generate efficiencies and accelerate clinical research.